IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

Neoadjuvant ipilimumab + nivolumab has demonstrated high pathologic response rates in stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less likely to benefit. We show that domatinostat (a class I histone deacetylase inhibitor) addition to anti-PD-1 + anti-CTLA-...

Descripción completa

Detalles Bibliográficos
Autores principales: Reijers, Irene L.M., Rao, Disha, Versluis, Judith M., Menzies, Alexander M., Dimitriadis, Petros, Wouters, Michel W., Spillane, Andrew J., Klop, Willem M.C., Broeks, Annegien, Bosch, Linda J.W., Lopez-Yurda, Marta, van Houdt, Winan J., Rawson, Robert V., Grijpink-Ongering, Lindsay G., Gonzalez, Maria, Cornelissen, Sten, Bouwman, Jasper, Sanders, Joyce, Plasmeijer, Elsemieke, Elshot, Yannick S., Scolyer, Richard A., van de Wiel, Bart A., Peeper, Daniel S., van Akkooi, Alexander C.J., Long, Georgina V., Blank, Christian U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037109/
https://www.ncbi.nlm.nih.gov/pubmed/36920329
http://dx.doi.org/10.1084/jem.20221952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037109/
https://www.ncbi.nlm.nih.gov/pubmed/36920329
http://dx.doi.org/10.1084/jem.20221952

Ejemplares similares